Postmenopausal Osteoporosis — Study of Transitioning From Alendronate to Denosumab
Citation(s)
A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women With Low Bone Mineral Density